WinstonWınston
Pfizer logo

Pfizer

PFE
47
Drug Manufacturers - General · Healthcare
Price
$25.05
-0.09 (-0.36%)
Market Cap
$142.77B
Winston Score
47
Winston is serious
Mixed quality — meaningful strengths and weaknesses.

Pfizer is one of the largest pharmaceutical companies in the world. It discovers, manufactures, and sells prescription medicines and vaccines to hospitals, pharmacies, doctors, and governments. Its well-known products include the Prevnar vaccine, the blood thinner Eliquis, and the COVID-19 vaccine it developed with BioNTech.

Pfizer makes most of its money by selling patented drugs at premium prices, then earning royalties and licensing fees on some products. It operates in over 125 countries and generates roughly half its revenue outside the United States. Its main competitive advantage is its large portfolio of patented medicines, which block competitors for years, along with its massive research and manufacturing infrastructure. The biggest risk Pfizer faces is patent expiration — several of its top-selling drugs will lose patent protection by the late 2020s, which could sharply reduce revenue unless new drugs from its pipeline successfully replace those sales.

Winston Score History

Politician Trades

21 trades / 12mo

9 Congressional buys and 12 sells on PFE in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+5.4% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-10.1% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$12.0B/ year

Rising (+12% vs prior year)

19.1% of revenue

In line with sector average (18%)

Investing heavily in future products and technology

Insider Activity

0.1%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$1.7B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Heavy R&D investment

Pfizer is putting 19% of revenue into R&D and that number is rising. And they're generating enough cash to self-fund it.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

0.4% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 5.71B (2021) → 5.69B (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
67.3%
Premium pricing power — 67.3% gross margin
Operating Margin
27.9%
Excellent — 27.9% operating margin
ROCE
2.6%
Weak — 2.6% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+1.4%
Nearly flat sales (1.4% YoY)
EPS YoY
-5.7%
Earnings shrinking (-5.7% YoY)

Slight earnings drop. Typical near a cyclical low.

EPS Consistency
2/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
160%
Turns 160% of profit into real cash
FCF Margin
15.0%
Converts sales into free cash efficiently (15.0%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.72
Moderate — manageable debt (0.72)
Interest Cover
5.53x
Adequate interest coverage (5.5x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
19.1x
Fair value — P/E 19.1

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

P/E vs Forward
+9.3
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (19.1 → 9.8)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield
7.25%
Healthy income — 7.25% yield

Yield above 6% — often a flag the market is pricing in a cut.

Dividend Growth
+0.6%
Dividend flat

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial